Chemotherapy as a Bridge to TIL Therapy in Refractory Melanoma
Dr. Ankit Mangla asks whether chemotherapy can bridge relapsed-refractory melanoma patients to TIL therapy, spotlighting the lymphodepletion bottleneck.
Topic
Topic
Dr. Ankit Mangla asks whether chemotherapy can bridge relapsed-refractory melanoma patients to TIL therapy, spotlighting the lymphodepletion bottleneck.